Table 4 Pathologic features of 40 thyroid cancers associated with BRAFV600E and TERT overexpression
Pathology (N = 40) | Negative BRAF/TERT N = 16 | BRAFV600E N = 20 | TERT N = 10 | BRAFV600E + TERT N = 6 |
|---|---|---|---|---|
Tumor type | ||||
 PTC | 13 | 18 | 6 | 4 |
 FTC | 3 | 0 | 0 | 0 |
 ATC | 0 | 2 | 4 | 2 |
Stage | ||||
 T-stage | ||||
  T1a | 8 | 4 | 1 | 0 |
  T1b | 3 | 5 | 3 | 2 |
  T2 | 1 | 3 | 0 | 0 |
  T3 | 3 | 5 | 2 | 2 |
  T4a | 1 | 1 | 0 | 0 |
  T4b |  | 2 | 4 | 2 |
 N-stage | ||||
  N0 | 13 | 1 | 1 | 0 |
  N1a | 3 | 10 | 3 | 3 |
  N1b | 0 | 9 | 6 | 3 |
LVI or PNI present (n = 14) | 2 | 10 | 3 | 1 |
Extrathyroidal extension (n = 13) | 3 | 8 | 6 | 4 |
Multifocal (n = 14) | 3 | 11 | 4 | 4 |